Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid
COPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.
from Reuters: Health News http://reut.rs/2qIS7Wm
http://bit.ly/2zwRqiM